Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
Strongbridge Biopharma plc (SBBP)
|
|
Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
In millions, except per share items | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 | Dec-31-13 |
| 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 20-F | 20-F |
Revenues | 100.0% | 100.0% | 100.0% | 100.0% | | | | |
Cost of goods sold | 7.2% | 17.6% | 554.4% | 21.0% | | | | |
Gross profit | 92.8% | 82.4% | -454.4% | 79.0% | | | | |
Selling, general and administrative | 133.0% | 225.9% | 351.3% | 515.1% | | | | |
Research and development | 83.9% | 142.3% | 141.1% | 245.1% | | | | |
EBITDA | -123.8% | -285.5% | 1037.2% | -681.1% | | | | |
Depreciation | 0.3% | 0.4% | 0.3% | 0.1% | | | | |
EBITA | -124.1% | -285.9% | 1036.9% | -681.2% | | | | |
Amortization of intangibles | 16.3% | 23.1% | 39.9% | 71.3% | | | | |
EBIT | -140.5% | -309.0% | 997.1% | -752.5% | | | | |
Pre-tax income | -146.7% | -219.6% | 179.7% | -1585.5% | | | | |
Income taxes | 0.0% | 8.1% | 3.0% | 25.1% | | | | |
Net income | -146.7% | -280.2% | 86.1% | -1610.6% | | | | |
|